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ABSTRACT
Treatment of severe acute and chronic gastrointestinal (GI) graft-versus-host disease (GVHD) with prolonged
high-dose systemic corticosteroids has limited success and considerable toxicity. Beclomethasone dipropionate
(BDP) is a potent topically active steroid. We treated 15 patients with acute (n  2) or chronic (n  13) GI
GVHD refractory to systemic corticosteroids with 28-day courses of oral BDP (2 mg 4 times daily). Response
was measured by the change in GI score (sum of 6 GI symptoms) as well as the ability to taper or discontinue
systemic corticosteroids. Nine (60%) of 15 evaluable patients responded to BDP, including 3 complete
responses (a GI score of 0 or 1 and discontinuation of systemic corticosteroids). Attempts to taper calcineurin
inhibitor during BDP therapy were unsuccessful. The 2 patients with acute GVHD had no response to BDP.
Responders received a median of 3 cycles (range, 1-20), compared with 1 cycle (range, 1-5) in nonresponders.
Suppression of the hypothalamic-adrenal axis was seen in 2 of the 5 patients tested, but neither demonstrated
clinically significant symptoms. We conclude that BDP is safe and effective for long-term treatment of chronic
GI GVHD.Multiple courses may be necessary to achieve or maintain response in some patients, and prolonged
BDP therapy is a feasible alternative to prolonged systemic corticosteroids.
© 2005 American Society for Blood and Marrow Transplantation
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fNTRODUCTION
Over the last 30 years, increasing numbers of pa-
ients with malignant and nonmalignant disorders
ave been treated with hematopoietic stem cell trans-
lantation (HSCT). With improvements in support-
ve care during the acute post-HSCT period, there is
growing population who experience long-term com-
lications of HSCT. Gastrointestinal (GI) complica-
ions are common after HSCT and can result from
onditioning regimen toxicity, infections, or graft-
ersus-host disease (GVHD). Acute GVHD remains a
ajor complication of allogeneic transplantation and
an occur in 30% to 35% of recipients of HLA-
atched sibling marrow and in 50% to 60% of recip-
ents of HLA-matched unrelated donors. Its occur-
ence is even higher in recipients of HLA-mismatched c
B&MTSCT [1]. The GI symptoms range from mild (an-
rexia only) or moderate (anorexia, nausea, vomiting,
nd diarrhea) to severe (disabling bloody diarrhea or
ntestinal ileus with intestinal mucosal cell necrosis
nd exfoliation, often lethal) [2-5].
GVHD diagnosed within 100 days after BMT is
enerally deﬁned as acute GVHD and is characterized
y epithelial cell injury mainly to the GI tract, liver,
nd skin. GVHD presenting after day 100 is deﬁned
enerally as chronic GVHD and is characterized by
brosis and atrophy of these and other organs. Occa-
ionally, the clinical picture of acute GVHD is seen
fter day 100. Treatment of acute or chronic GI
VHD is a challenge because it can be refractory to
rontline immunosuppression. High-dose systemic
orticosteroids are used with some success and signif-
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5cant toxicity. The risks of prolonged immunosup-
ression include local and disseminated infection,
pstein-Barr virus–associated lymphoproliferative
isease, hypothalamic-pituitary-adrenal axis suppres-
ion, myopathy, glucose intolerance, neuropsychiatric
isease, and bone demineralization [4-6].
Beclomethasone dipropionate (BDP) is a potent,
opically active corticosteroid that is used to suppress
ntestinal inﬂammation in Crohn’s disease and ulcer-
tive colitis—both conditions that can resemble
VHD in symptomatology and as inﬂammatory dis-
ases [7]. Systemic adverse effects are limited by in-
omplete absorption and intestinal hydrolysis of the
ropionate residues [8,9]. Once absorbed, BDP is con-
erted to beclomethasone, which is a weak steroid that
s degraded by the liver. Investigators have reported
esults of the Seattle experience with end organ–tar-
eted therapy for patients with less severe forms of
ntestinal acute GVHD. This experience demon-
trated that effective therapy can be achieved with
inimal toxicity. They reported a response rate of
7% with BDP alone and 64% with BDP in combi-
ation with prednisone [10]. A second randomized
lacebo-controlled trial demonstrated a beneﬁt of
dding oral BDP to prednisone (71% versus 41%; P
02) [11]. End points used in these studies were im-
roved caloric intake and decreased diarrhea. These
romising single-institution clinical data formed the
ationale for this prospective trial of long-term oral
DP in patients with methylprednisolone (MP)–re-
ractory acute or chronic GI GVHD. Both previously
eported trials used a short course of BDP (28 days).
e describe the feasibility and safety of prolonged
DP use for patients with GI GVHD.
ETHODS
atient Population
This was a single-institution compassionate use
tudy with no predetermined target accrual goal, and
ata collection and analysis were performed solely by
he authors. Between 1998 and 2003, 19 patients with
cute or chronic GVHD refractory to frontline im-
unosuppression were enrolled in a phase II trial of
ral BDP under an institutional review board–ap-
roved protocol at Roswell Park Cancer Institute. All
atients signed informed consent. “Refractory to
rontline immunosuppression” was deﬁned as patients
ho had progressive GI tract GVHD despite thera-
eutic levels of calcineurin inhibitor (CI) and MP or
ts equivalent at a dose of 1 to 2 mg/kg for at least one
eek. In addition, patients with therapeutic levels of
I and who could not be weaned off steroids without
ﬂare of GI tract GVHD were also considered not
esponsive to standard therapy.All patients were initially treated for GVHD with o
88oncomitant CI and MP. CI was continued during
reatment for acute and chronic GVHD. The treat-
ent strategy after initiation of BDP was to continue
I at therapeutic levels and attempt to wean steroids
rst, followed by an attempt to taper the CI.
Inclusion criteria were (1) a clinical and/or patho-
ogic diagnosis of GVHD of the GI tract, (2) age 5
ears but 70 years, (3) the ability to swallow medi-
ation, (4) the absence of GI infection conﬁrmed by
egative stool cultures and Clostridium difﬁcile assay,
nd (5) unsuccessful or contraindicated standard ther-
py for GVHD with systemic immunosuppressive
gents because of intolerance. Exclusion criteria were
1) clinically signiﬁcant intestinal infection conﬁrmed
y stool culture and (2) persistent vomiting.
Patients underwent allogeneic stem cell transplan-
ation by using either a myeloablative (n  14) or
educed-intensity (n  1) conditioning regimen with
r without total body irradiation followed by stem cell
nfusion. The stem cell source was bone marrow (n 
), peripheral blood (n 4), or cord blood (n 5). Of
he 13 patients treated for chronic GVHD, 9 patients
ad prior acute GVHD (grade I, n  2; grade II, n 
; grade III, n  5). Patient characteristics are sum-
arized in Table 1.
DP Treatment
Pretreatment studies included (1) stool cultures
or C difﬁcile toxin, bacterial cultures, and ova and
arasite detection within 1 week of the start of treat-
ent; (2) stool cultures for viral and fungal infections
ithin 2 weeks of the start of treatment; (3) weight in
ilograms; (4) documentation of Karnofsky/Lansky
erformance status; (5) serum albumin and total pro-
ein determination; and (6) GI symptom score. An
ggregate GI symptom score was obtained by adding
point for the presence of each of the following
ymptoms: anorexia, nausea, vomiting, diarrhea, ab-
ominal pain, and weight change 5% of body
eight. At enrollment, all patients had a baseline GI
ymptom score from 1 to 6.
Assessments during therapy included (1) GI symp-
om score before each new cycle; (2) evaluation and
ocumentation of skin, GI, and liver GVHD every
eek; (3) evaluation and documentation of clinically
igniﬁcant infections every week; (4) toxicity evalua-
ion every week; (5) serum albumin and total protein
evels monthly; (6) cortisol stimulation test if clinically
ndicated and in patients receiving 6 or more cycles
the BDP dose was withheld on the morning of the
est); (7) weight every 2 weeks; and (8) change in
ystemic steroid dose as a percentage of baseline at the
nd of each treatment course for any reason (GI or
xtraintestinal GVHD).
BDP was administered orally as a pill or as a corn
il emulsion (for preparation of the emulsion, 250 mg
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Oral BDP in Gastrointestinal GVHD
Bf BDP powder purchased from Spectrum Chemical
anufacturing Corporation [Gardena, CA] was
laced in 500 mL of corn oil by the Roswell Park
ancer Institute pharmacy). BDP was given orally 4
imes a day at a dose of 2 mg (ie, a total daily dose of
mg). Patients initially received one 28-day course of
DP therapy. Upon initiation of each cycle of BDP,
n attempt was made to taper systemic corticosteroids
t the discretion of the treating clinician. In patients
ho could tolerate discontinuation of systemic corti-
able 1. Patient Characteristics
Characteristic
Responders
(n  9)
Nonresponders
(n  6)
edian age, y (range) 34 (5-51) 46.5 (6-53)
ex (M/F) 7/2 3/3
VHD
Acute 0 2
Chronic 9 4
edian days after
transplantation at
start of BDP (range) 431 (265-1529) 109 (39-251)
edian steroid dose at
start of BDP,
milligrams of
prednisone/day
(range) 19 (0*-88) 113 (5-188)
nderlying diagnosis
Acute leukemia 4 0
Chronic leukemia 4 1
Non-Hodgkin lymphoma 1 2
Nonmalignant
hematologic disorder 0 3
ransplantation
characteristics
Donors
Related 5 3
Unrelated 4 3
Source
Peripheral stem cells 2 2
Bone marrow 4 2
Cord blood 3 2
HLA matched
Yes 6 2
No 3 4
Sex match
Yes 3 5
No 6 1
Conditioning
Total body irradiation
based 5 3
Chemotherapy based 4 3
Conditioning intensity
Myeloablative 9 5
Reduced intensity 0 1
VHD prophylaxis†
CS or FK  Mt 
MP[13,14] 5 5
CS or FK  MP[15] 3 1
FK  OKT3  MP[16] 1 0
One patient was intolerant of oral steroids.
GVHD prophylaxis regimens; CS, cyclosporine; FK, FK506, or
tacrolimus; Mt, methotrexate; MP, methylprednisolone; OKT3,
Orthoclone anti-CD3 monoclonal antibody.osteroids without a ﬂare of GVHD symptoms, an t
B&MTttempt to wean and discontinue CI was then made. In
atients with improved GI scores, an attempt to taper
DP on day 22 was at the discretion of the treating
linician. Response assessment was performed on day
8 of BDP therapy. A second course of extended BDP
herapy was given if symptoms of GI GVHD persisted
r to maintain GI response. Toward the end of the
econd course (day 22), an attempt was made to taper
he BDP if there were no symptoms of GI GVHD.
tarting on day 22 of the second therapy course, the
DP dose was tapered as follows: BDP 2 mg thrice
aily for 3 days, then BDP 2 mg twice daily for 3 days,
nd then BDP 2 mg once a day on the last therapy day.
atients could receive up to 6 treatments per year, but
n attempt to wean had to be undertaken at least
nnually. A new informed consent had to be signed
fter every 2 cycles for continuation of therapy.
Treatment was modiﬁed by using the following
uidelines: BDP was withheld if patients developed
ersistent vomiting until resolution of this problem.
atients who vomited a dose of BDP within 30 min-
tes of taking the medication were allowed to repeat
he dose immediately. Patients who experienced eme-
is with the replacement dose resumed therapy as
cheduled at the next dose time point. Patient com-
liance with BDP therapy was assessed by direct ques-
ioning weekly and during follow-up visits.
esponse Assessment
We enrolled 19 patients over a 5-year period.
owever, only 15 patients went on to receive at least
complete cycle of therapy, and results from these 15
valuable patients are presented. Four patients were
onevaluable for the following reasons: 2 did not re-
eive therapy (1 because of progression of underlying
isease and the other because of cytomegalovirus en-
eritis), 1 patient stopped therapy after 4 days because
f intractable nausea and was not rechallenged with
DP, and the fourth patient stopped therapy after 2
ays of BDP therapy because stool cultures were pos-
tive for enterovirus.
Response was deﬁned as follows: complete re-
ponse was deﬁned as the resolution of GI symptoms
GI score of 0 or 1) and complete taper of systemic
teroids, whereas partial response was deﬁned as an
mprovement in GI score from baseline with stable or
ncomplete tapering of systemic steroids. Patients who
ad no improvement, who had worsening GI scores,
r who required any increase in their systemic steroid
ose were classiﬁed as nonresponders. All adverse
vents were reviewed by the principal investigator at
he completion of each treatment course and on an
s-needed basis.
Descriptive statistics were used to summarize pa-
ient characteristics. Treatment follow-up occurred
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5hrough August 31, 2003, and survival was last up-
ated on February 28, 2004.
ESULTS
Patients were enrolled on study a median of 265
ays (range, 39-1529 days) after transplantation. Pa-
ient characteristics are summarized in Table 1. All
DP-treated patients with MP-refractory severe GI
VHD received at least 1 course of BDP therapy. All
atients but 1 had received MP 2 mg/kg/d as prior
herapy for GI GVHD and had no symptom relief.
he remaining patient did not tolerate MP.
linical Efficacy
Fifteen of 19 patients were evaluable for response
o BDP. Nine (60%) of 15 patients responded to BDP
s measured by improvement or complete resolution
f GI symptoms and the ability to taper steroids.
here were 3 complete responses (20%) and 6 partial
esponses (40%) as deﬁned in “Methods.” There were
o patients who were able to discontinue CI therapy
hile receiving BDP therapy. Baseline GI scores, ste-
oid doses, number of cycles administered, and treat-
ent outcomes are shown in Table 2. Three patients
ere still receiving therapy at the time of this writing.
hree of the 9 responders have died as a result of
elapse of underlying disease (n  1), GVHD (GI and
kin; n  1), or infection (n  1). Five of the 6
onresponders have died as a result of either GVHD
n  3) or infection (n  2). The median number of
ycles of BDP in all patients was 2 (range, 1-20).
here was no time interval between BDP cycles in
atients receiving 2 or more cycles; cycles were ad-
inistered continuously. Responders received a me-
ian of 3 cycles (range, 1-20), whereas nonresponders
eceived a median of 1 cycle (range, 1-5). Character-
stics of the responders and nonresponders are sum-
arized in Table 1. The reasons for withdrawal from
DP therapy are stated in Table 2. Three patients
ho achieved a partial response had to prematurely
erminate therapy (ulcer irritation in 1 subject and a
ecline in performance status necessitating mechani-
al ventilation in 2 subjects). Three patients had im-
roved GI scores on therapy (Table 2) but were clas-
iﬁed as nonresponders because of an increase in their
ystemic corticosteroids for nonintestinal GVHD
skin, n  2; lung, n  1). There was no apparent
ifference in efﬁcacy between pills and suspension but
here were likely not enough patients to note a signif-
cant difference.
oxicity
Adrenal axis function. Adrenal axis testing was per-
ormed in 5 patients. During the course of BDP ther-
py, only 2 patients met the criteria for adrenal axis d
90uppression that was thought to be related to therapy.
n both cases, suppression of the hypothalamic-adre-
al axis was asymptomatic and did not require sys-
emic steroid hormone replacement. One patient had
eceived 15 cycles (15 months) and was not receiving
ystemic corticosteroids because of intolerance; the
ther was tapered off systemic corticosteroids after
ycle 10 and received a total of 20 cycles (20 months)
f BDP treatment.
Infections. While receiving BDP therapy, 1 of the 2
atients with acute GVHD and 6 of the 13 patients
ith chronic GVHD developed invasive viral and or
ungal infections. There was no apparent relationship
etween infection and the number of cycles of BDP.
hese infections are summarized in Table 2.
ISCUSSION
This is the ﬁrst report of the safety and efﬁcacy of
ultiple courses of BDP administered for GI GVHD.
n this series of severe GI GVHD, there was a 20%
omplete response rate (total or nearly total resolution
f GI symptoms and complete taper of systemic ste-
oids) and a 40% partial response rate (improvement
f GI scores and incomplete steroid taper or stable
teroid requirement). We believe that the use of a
ombination of an improved GI symptom score and
he ability to taper systemic steroids is a clinically
eaningful end point and that it provides a better
nderstanding of the beneﬁt that can be expected with
his therapy. These results are comparable to those
oted by McDonald et al. [11] (71%) and are also
imilar to those expected from systemic MP use (50%-
0%). However, different criteria were used to mea-
ure response. In this study, we included all patients
ith refractory severe GI GVHD. The median steroid
ose for all patients was 75 mg/d of the equivalent of
ral prednisone at baseline (range, 0-187.5 mg/d).
ur results indicate that successful tapering of ste-
oids can be achieved even in patients receiving very
igh doses of steroids.
The strength of the study is the prospective nature
f the trial; this is the ﬁrst report of long-term use
ith no serious adverse events. Seven patients had
iral or fungal infections on BDP therapy. Three of
hese patients are alive, and 2 are responders who
emain on therapy. In this experience, oral BDP was
ot found to increase the risk for opportunistic infec-
ions, because infection was a cause of death in only 1
atient, who underwent cord blood transplantation
nd died of Mycobacterium chelonae pneumonia. Symp-
om improvement was seen after 1 cycle in all re-
ponders, but a median of 3 cycles of therapy were
ecessary to maintain or prolong beneﬁt. The clinical
tility of oral BDP for GI GVHD remains to be
eﬁned by randomized controlled trials. A prospective
Table 2. Results of Oral BDP Treatment in 15 Evaluable Patients
Patient GVHD
No.
Courses
Steroid
Dose
before BDP
(mg/d)*
Steroid Dose at
End of BDP (mg)*
% Change
in Steroid
Dose
GI
Score at
Baseline
GI
Score
after
First
Cycle
GI Score at
Time of
Discontinuing
BDP or at
Present
Viral/Fungal
Infections While
on Therapy
Reason for
Discontinuation
Cause of
Death
Complete response
(CR)
1 C 5 19 0 100 4 1 0 None CR Disease
2 C 3 88 0 100 3 1 1 None CR Alive
3 C 20 8 0 100 3 0 0 Aspergillus, lung Still on BDP Alive
Partial response
(PR)
1 C 5 25 5 79 4 0 0 None Still on BDP Alive
2 C 1 10 10 0 1 0 0 None GI ulcer
irritation
Alive
3 C 2 30 1 (every other day) 98 6 1 1 None PR Alive
4 C 15 0 0 N/A 6 1 3 CMV antigenemia Still on BDP Alive
5 C 1 75 75 0 2 1 1 CMV antigenemia,
lung
Intubation GVHD
6 C 2 10 10 0 5 4 3 Mycobacterium
chelonae, lung
Intubation Infection
No response (NR)
1 C 4 113 238 111 5 1 2 Candida glabrata,
blood
Intubation GVHD
2 C 5 5 53 950 4 1 1 Candida albicans,
blood
NR Alive
3 A 1 88 463 428 4 4 4 Fusarium,
onychomycosis
Intubation GVHD
4 C 1 138 88 36 5 5 5 None NR GVHD
5 A 1 188 38 80 1 1 1 None GI bleed Infection
6 C 1 113 113 0 1 1 1 None Intubation Infection
C, indicates chronic GVHD; A, acute GVHD; CMV, cytomegalovirus; N/A, not applicable.
*Methylprednisolone or its equivalent dose in milligrams.
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5lacebo-controlled trial examining the use of BDP
ith prednisone for acute moderate GI GVHD has
een completed [17]. Future studies of oral BDP must
onsider an alternate vehicle of delivery to improve
alatability, because the corn oil suspension was re-
orted by patients to be only marginally palatable.
ormulating BDP as caplets may be better tolerated
unpublished results). Another oral steroid, budes-
nide (3 mg/5 mL saline 2-3 times a day for 3
onths), has been studied in the setting of resistant
ral GVHD, and objective responses were assessed by
he treating physicians according to the gross appear-
nce of lesions [12]. This formulation has not been
valuated in the setting of extensive or more distal GI
VHD, and there was no report of an attempt to
aper systemic steroids in responding patients.
The limitations of our study are the sample size,
he limited number of subjects treated for acute
VHD, and the lack of adrenal axis testing in all
atients. Adrenal axis testing was performed only
hen it was clinically indicated and in the 2 patients
ho received more than 6 months of therapy (15 and
0 cycles), and no clinically relevant adrenal axis sup-
ression was noted from prolonged oral BDP use. As
eported by Baehr et al.[10], systemic absorption
robably occurs, but clearly it is not necessary for
fﬁcacy, because 3 of 5 patients who were tested had
ormal adrenal axis function and yet responded. The
ource of stem cells (bone marrow, peripheral blood
tem cells or cord blood) and HLA match status did
ot appear to inﬂuence response to therapy, however
his may reﬂect the small sample size.
Combining relatively nontoxic topical therapy to
inimize the use and, hence, adverse effects of sys-
emic immunosuppression makes BDP an attractive
gent to add to our therapeutic strategy. Oral BDP is
afe and effective in the setting of steroid-resistant
hronic GI GVHD and can be administered long
erm.
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